Tuesday, December 14, 2010
Chimerix Inc., of Durham, N.C., said Phase I results demonstrated that CMX157 has a favorable safety, tolerability and drug distribution profile. In addition, results from preclinical studies showed that the drug exhibited potent in vivo activity against HIV, including HIV strains resistant to current therapies, and potent in vitro activity against xenotropic murine leukemia virus-related virus. Data were presented at the HIV DART 2010 meeting in Los Cabos, Mexico. CMX157 is a chemically modified version of tenofovir using the company's Phospholipid IntramembraneMicrofluidization Conjugate technology.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.